CA
NTLA icon

CoreCap Advisors’s Intellia Therapeutics NTLA Stock Holding History

CoreCap Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Buy
+1
New +$14 ﹤0.01% 3149
2025
Q2 		– Sell
-29
Closed -$206 – 3079
2025
Q1 		$206 Buy
+29
New +$293 ﹤0.01% 2967

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

CoreCap Advisors's NTLA Position: Q2 2026 in Review

CoreCap Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 1 share worth $17. The stake represents ﹤0.01% of the portfolio and ranks #3149 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in NTLA as recently as Q1 2025.

CoreCap Advisors first reported a position in NTLA in Q1 2025 and has held it in 2 quarters since. The position peaked at $206 in Q1 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • CoreCap Advisors held 1 share of Intellia Therapeutics worth $17 as of Q2 2026.
  • Intellia Therapeutics was a new CoreCap Advisors position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3149 holding.
  • CoreCap Advisors first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • CoreCap Advisors's Intellia Therapeutics position peaked at $206 in Q1 2025.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.